

PAUL SHEARER TO JOIN THE BOARD AND JOHN PINION TO RETIRE.

Aroa Biosurgery Limited (ASX: ARX) ("AROA" or "the Company") today announces the appointment of Paul Shearer as a Non-Executive Director, effective Friday 31 October 2025.

Mr. Shearer is an accomplished global healthcare executive with extensive experience in the medical device industry and a proven record of leading international sales growth.

He previously spent over three decades with Fisher & Paykel Healthcare, including 20 years as Senior Vice President, Sales & Marketing, where he led global commercial operations across more than 50 markets and played a key role in the company's successful sales expansion in the United States.

Earlier in his career, Mr. Shearer held senior roles in the technology sector with Computercorp Ltd and ICL Ltd before joining Fisher & Paykel Healthcare. He is also a current Director of Skellerup Holdings Limited.

Brian Ward, AROA CEO, said: "Paul's experience leading the international sales growth of a New Zealand headquartered medical device company, including a strong track record in the United States, will provide valuable insight as AROA continues to scale. On behalf of the team at AROA, I extend a warm welcome to him."

The company also announces that on the same date, John Pinion will retire from the Board. Mr. Pinion, a United States based medtech executive, has been on AROA's Board of Directors since 2015.

Jim McLean, AROA Board Chair, said: "On behalf of the Board, I would like to thank John for his significant contribution over the past 10 years. John's experience and insight have helped guide the Company through a number of important milestones. We wish him well for the future.

I am also pleased to welcome Paul to the Board. He brings deep global commercial experience that will strengthen the Board's oversight as AROA continues to execute its growth strategy."

Mr. Shearer will stand for election at AROA's next Annual General Meeting.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact Details

Sarah Tora
Corporate Communications Manager
+64 21 531043
sarah.tora@aroa.com

About AROA

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for *everybody*'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has commercialised four product families based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in more than 50 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com.